Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

(SWOG Cancer Research Network) Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news